Skip to main content
Amneal Pharmaceuticals
  • Corporate (opens in a new tab)
  • India (opens in a new tab)
International
Ask us anything:
  • About
        • About We challenge convention so healthy can be possible
        • Our Story
          • Amneal at-a-glance
          • Our Founders
          • Our Milestones
        • Our Purpose & Commitments
        • Our Culture
          • Rise, Lead, Succeed
        • Our Leadership
          • Executive Leadership
          • Board of Directors
        • Our Locations
        • Responsibility
          • The Amneal Patient Assistance Programs
          • Product Donations
          • National & Local Philanthropy
          • Compliance and Ethics
        • Patient Community Connections
          • Our Commitment to Parkinson's
        • Awards & Recognition
  • Products
        • Products We create essential medicines
        • Our Portfolio
          • Biosciences
          • Generic Products
          • Specialty Products
          • Product Catalog
        • Quality
        • Drug Safety
          • Adverse Event Reporting
          • Medical Inquiries
          • Product Complaints
        • Operations
  • Research & Development
        • Research & Development We invest significantly in new product development
        • Generics R&D
        • Specialty R&D
          • Drug Delivery Technologies
        • Product Partnering
  • Investors
        • Investors Become an Informed Investor
  • News
  • Careers
        • Careers Help make healthy possible
        • Total Rewards
        • Search Our Career Opportunities
  • Contact
  • Customer Login
  • Investor Relations
  • Financial Reports
    • SEC Filings
    • Annual Reports
    • Quarterly & Other Reports
  • Events & Presentations
  • Stock Information
  • Corporate Governance
    • Policies
    • Executive Officers & Directors
    • Board Committees
  • Investor Resources
    • Analysts
    • Investor FAQ
    • Email Alerts
    • Information Request
    • RSS Feeds

Home Home  >  News  >  Press Releases

  • Investor Relations
  • Financial Reports
    • SEC Filings
    • Annual Reports
    • Quarterly & Other Reports
  • Events & Presentations
  • Stock Information
  • Corporate Governance
    • Policies
    • Executive Officers & Directors
    • Board Committees
  • Investor Resources
    • Analysts
    • Investor FAQ
    • Email Alerts
    • Information Request
    • RSS Feeds
Normal
Press Release RSS Feed (opens in new window)
Press release year list 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002
Dec 20, 2022
Amneal Announces 26 Generic New Product Launches in 2022 and First Injection Large Volume Bag Approval
Nov 23, 2022
Amneal to Participate at Upcoming Investor Conferences
Nov 22, 2022
Amneal Launches Second Biosimilar with RELEUKO® (filgrastim-ayow) in the United States
Nov 11, 2022
Amneal Announces U.S. FDA Filing Acceptance of New Drug Application for IPX203 for the Treatment of Parkinson’s Disease
Nov 04, 2022
Amneal Reports Third Quarter 2022 Financial Results
Nov 02, 2022
Amneal Receives FDA Approval for Leuprolide Acetate Injection
Oct 31, 2022
Amneal Expands Leadership Team with Appointment of Senior Leaders in Quality and Regulatory
Oct 06, 2022
Amneal to Report Third Quarter 2022 Results on November 4, 2022
Oct 03, 2022
Amneal Launches First Biosimilar with ALYMSYS® (bevacizumab-maly) in the United States
Sep 06, 2022
Amneal Appoints Gustavo Pesquin as Executive Vice President, Chief Commercial Officer – Specialty
Aug 31, 2022
Amneal Announces Submission of New Drug Application to the U.S. FDA for IPX203 for the Treatment of Parkinson’s Disease
Aug 22, 2022
Amneal supports Congress’ efforts to ensure essential medicines are Made in America
Aug 11, 2022
Amneal launches 4 new Generic products, including Vasopressin single-dose
Aug 05, 2022
Amneal Reports Second Quarter 2022 Financial Results
Aug 03, 2022
Amneal Appoints Deborah M. Autor to Board of Directors
Jul 08, 2022
Amneal to Report Second Quarter 2022 Results on August 5, 2022
Jun 07, 2022
Amneal Releases 2021 Corporate Responsibility Report Highlighting Continued ESG Impact and Integration
Jun 01, 2022
Amneal Launches LYVISPAH® (baclofen) for Spasticity Related to Multiple Sclerosis and Other Spinal Cord Disorders
May 27, 2022
Amneal Achieves Third U.S. Biosimilar Approval with FYLNETRA™ (pegfilgrastim-pbbk)
May 24, 2022
Amneal to Participate at the 2022 Jefferies Healthcare Conference
May 13, 2022
Amneal to Participate at Upcoming Investor Conferences in May
May 04, 2022
Amneal Reports First Quarter 2022 Financial Results
Apr 13, 2022
Amneal Achieves Second U.S. Biosimilars Approval with ALYMSYS® (bevacizumab-maly)
Apr 07, 2022
Amneal to Report First Quarter 2022 Results on May 4, 2022
Mar 24, 2022
Amneal to Present Results From the Pivotal Phase 3 RISE-PD Clinical Trial of IPX-203 at the 2022 American Academy of Neurology Annual Meeting
Mar 17, 2022
Amneal Awarded Sub-License to Manufacture and Commercialize Generic Version of Co-Packaged Nirmatrelvir and Ritonavir in 95 Low- and Middle-Income Countries
Mar 02, 2022
Amneal Reports Fourth Quarter and Full Year 2021 Financial Results
Mar 01, 2022
Amneal Enters U.S. Biosimilars Market With Approval of RELEUKO® (filgrastim-ayow)
Feb 17, 2022
Amneal Expands Injectables Portfolio with 4 New Products
Feb 04, 2022
Amneal to Report Fourth Quarter and Full Year 2021 Results on March 2, 2022
Jan 05, 2022
Amneal Acquires Saol Therapeutics’ Baclofen Franchise

Investor Faq

Get answers to important investor relation questions.

More

Investor Tools

  • Email Alerts
  • RSS Feeds
  • Email Page

IR Contact

Get answers to your investor relation questions.

More
  • Privacy Policy
  • Copyright & Legal Disclaimer
  • Web Accessibility
© Amneal Pharmaceuticals LLC.
All rights reserved.
Powered By Q4 Inc. 5.96.0.15 (opens in new window)
Back to top